secwatch / observer
8-K filed May 5, 2026, 7:59 PM ET ticker DTIL CIK 0001357874
earnings confidence high sentiment neutral materiality 0.70

Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing

PRECISION BIOSCIENCES INC

2026-Q1 EPS reported -$0.75 revenue$10,838,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001628280-26-030123
form_type
8-K
ticker
DTIL
cik
0001357874
company_name
PRECISION BIOSCIENCES INC
filed_at
2026-05-05T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.186291+00:00
generated_at
2026-05-14T23:17:47.807736+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
neutral
materiality_score
0.7
calibrated_materiality_score
0.7
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001628280-26-030123
json_url
https://secwatch.observer/filing/0001628280-26-030123.json
markdown_url
https://secwatch.observer/filing/0001628280-26-030123.md
text_url
https://secwatch.observer/filing/0001628280-26-030123.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/0001628280-26-030123-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1357874/000162828026030123/dtil-20260505.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

d9057e6d4e3b09cbe417f2e71a94c99475804842

PRECISION BIOSCIENCES INC reported financial results for first quarter ended March 31, 2026.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

GTLB

GitLab Q1 revenue $264M (+23% YoY); plans 14% workforce cut, $30-35M charges

Gitlab Inc. June 2, 2026, 4:17 PM ET earnings Items 2.02, 2.05, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

in such filing. --- EX-99.1 (EX-99.1) --- GitLab Reports First Quarter Fiscal Year 2027 Financial Results First Quarter Fiscal Year 2027 Highlights: • Total revenue of $264.2 million, up 23% year-over-year • GAAP operating margin of (6)%; non-GAAP operating margin of 14% • Operating cash flow of $149.2 million and non-GAAP adjusted free cash flow of $146.7

Filing page SEC filing

PETS

PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment

PETMED EXPRESS INC June 2, 2026, 4:15 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. • Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.

Filing page SEC filing

SPWH

Sportsman's Warehouse Q1 net sales up 2.8% to $256.1M; same-store sales +2.1%; net loss $21.8M

SPORTSMAN'S WAREHOUSE HOLDINGS, INC. June 2, 2026, 4:10 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

and generating positive free cash flow to further strengthen our balance sheet through debt reduction.” For the thirteen weeks ended May 2, 2026: • Net sales increased 2.8% to $256.1 million, compared to $249.1 million in the first quarter of fiscal year 2025. Performance was driven primarily by a 7.4% gain in Hunting and Shooting Sports, led by firearms, ammunition,

Filing page SEC filing

ULTA

Ulta Q1 net sales +11.1% to $3.16B, comps +5.3%; FY EPS guidance raised to $28.36-$28.80

Ulta Beauty, Inc. June 2, 2026, 4:06 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

compared to the same period ended May 3, 2025 : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 13 Weeks Ended ​ ​ May 2, ​ May 3, (Dollars in millions, except per share data) ​ 2026 ​ 2025 Net sales ​ $ 3,163.9 ​ $ 2,848.4 Comparable sales ​ ​ 5.3% ​ ​ 2.9% Gross profit (as a percentage of net sales) ​ ​ 40.1% ​ ​ 39.1% Selling, general and administrative expenses ​ $ 814.7 ​ $ 710.6

Filing page SEC filing

YEXT

Yext Q1 FY27: Adj EBITDA margin 25%, ARR $440.8M; boosts buyback by $100M

Yext, Inc. June 2, 2026, 4:05 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

Exchange Act, except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Yext Announces First Quarter Fiscal 2027 Results – Revenue of $107.9 million – Net Income Per Share, basic, of $0.02 or non-GAAP Net Income Per Share of $0.15 – Adjusted EBITDA of $26.9 million, resulting in an Adjusted EBITDA margin of 25% – ARR of

Filing page SEC filing

IVF

INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

INVO Fertility, Inc. June 2, 2026, 8:40 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue from all clinics was $8,021,929, including

Filing page SEC filing

POLA

Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%

Polar Power, Inc. June 2, 2026, 8:30 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %

Filing page SEC filing

CTRN

Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M

Citi Trends Inc June 2, 2026, 6:58 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Comparable filing

(EXHIBIT 99.1) --- EX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER FISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth of 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million; Q1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results

Filing page SEC filing

Source: SEC EDGAR
accession 0001628280-26-030123
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.